Learn how you can improve quality and patient care with data-related tools and resources—free for ASNC Members!
Read the latest science in the official publication of the American Society of Nuclear Cardiology.
Membership provides valuable resources to help you achieve your nuclear cardiology career goals.
Welcome to the new home for ASNC education.
Get the latest PatientFirst and chest pain tools and resources for your lab.
The Centers for Medicare & Medicaid Services (CMS) released the 2024 Medicare Physician Fee Schedule (MPFS) and the Hospital Outpatient Prospective Payment System (HOPPS) final rules. Your advocacy team is analyzing both rules and will report to you on specifics that may impact your practice. The following is ASNC's top-line analysis:
The results of the AURORA (International Study to Evaluate Diagnostic Efficacy of Flurpiridaz [18F] Injection PET MPI in the Detection of Coronary Artery Disease [CAD]) trial were published Oct. 9, in the Journal of the American College of Cardiology. The authors, led by Jamshid Maddahi, MD, FASNC, reported that PET imaging with flurpiridaz significantly exceeded prespecified threshold criteria for detection of CAD and was superior to Tc-labeled SPECT myocardial perfusion imaging for detection of CAD in the overall population and in women and obese patients.
Speaking at ASNC2023's Opening Plenary Session, Mouaz H. Al-Mallah, MD, MSc, MASNC, announced an advocacy win that speaks to ASNC's perseverance. For more than two years, ASNC leaders have been talking with Evicore about expanding their coverage policy to include PET myocardial blood flow (MBF). "As of now, Evicore no longer considers myocardial blood flow experimental," Dr. Al-Mallah announced. "This is an important success for ASNC and, more importantly, for patient care."